CARDIFF ONCOLOGY, INC. Treasury Stock Acquired, Average Cost Per Share
CARDIFF ONCOLOGY, INC. (CRDF) had Treasury Stock Acquired, Average Cost Per Share of $3.51 per share as of 2024-05-30, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2026-02-24
- 2024-05-30: Treasury Stock Acquired, Average Cost Per Share $3.51.
| Period end | Treasury Stock Acquired, Average Cost Per Share |
|---|---|
| 2024-05-30 | $3.51 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |